Over 3 billion PPI inhibitor "Esomeprazole sodium" added to the mix!

Esomerazole is a single L-isomer of omeprazole, with fast, long-lasting and stable acid suppressant characteristics, the drug was first developed by astraZenecaAB of Sweden, in 2000 oral dosage form in Sweden, in 2003 injection type on the market.
has been listed in China's main dosage forms are intestinal tablets, intestinal capsules and injections.
injection of sodium Esomeprazole is mainly used for: 1, as an alternative therapy for gastroesophageal reflow disease when oral therapy is not applicable; Low-risk patients (gastroscopic Forrest grade IIc-III); 3, used to reduce the risk of bleeding after endoscopic treatment of stomach and terse ulcers in adults; 4, prevention of stress ulcer bleeding in severe patients.
domestic public sales data show that in 2019, public medical institutions terminal injection of Esomelazole sodium sales have exceeded 3 billion yuan.
, AstraZeneta's (AZ) original research product, AstraZeneta, had a market share of 51.48 percent.
According to the pharmaceutical data enterprise version of hospital sales data show that in 2019 injection of Esomela sodium domestic sample hospital sales of 540 million yuan, of which the original research still accounted for 70.69 percent of the share, followed by Zheng Tianqing, accounting for 16.12 percent of the share.
According to the latest industry news, the fourth batch of harvesting is expected to open in January 2021, yesterday (12 and 8) the State Drug Organization department held a provincial collection of drugs, supplies, national mining symposium, the meeting mainly discussed the national drug collection, consumables collection, collection and renewal, implementation, local collection experience and ideas, the next drug and supplies Collection and collection consideration, etc. , at the same time, the national collection is also discussed, industry professionals pointed out that the number of national collection of the fourth batch of catalog products may reach a new high; in fact, not long ago, there have been industry authorities pointed out that the fourth batch of collection program is screening varieties;
At present, there are 40 approvals for the domestic injection of Esomeprazole sodium market, involving 34 manufacturers; Esomerazole sodium (commodity name: Essopine) is the first heavy-duty drug to enter the field of digestion, but also the first declared, the first batch of approved injection of Esomerazole sodium, with 20mg and 40mg specifications, officially launched in May 2016.
Now Lemei Pharmaceuticals to the new chemical drugs 4 categories of registration and listing was approved, as if through the consistent evaluation, in the upcoming fourth batch of collection, collection varieties to expand only injections, as a large variety of on-site drug use, and has been evaluated by 2 enterprises, forming a "2-1" collection competition pattern, is expected to be included in a new round of collection, will inevitably usher in a new round of price reduction tide, and through price exchange to obtain more terminal hospital market share.
。